CN100368022C - Dual targeting anti-hepatic fibrosis drug carrier mimic glycoprotein nanoparticle and its preparation method - Google Patents
Dual targeting anti-hepatic fibrosis drug carrier mimic glycoprotein nanoparticle and its preparation method Download PDFInfo
- Publication number
- CN100368022C CN100368022C CNB2005100297841A CN200510029784A CN100368022C CN 100368022 C CN100368022 C CN 100368022C CN B2005100297841 A CNB2005100297841 A CN B2005100297841A CN 200510029784 A CN200510029784 A CN 200510029784A CN 100368022 C CN100368022 C CN 100368022C
- Authority
- CN
- China
- Prior art keywords
- mannopyranose
- nanoparticle
- neoglycoproteins
- preparation
- phosphoric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000003886 Glycoproteins Human genes 0.000 title claims abstract description 50
- 108090000288 Glycoproteins Proteins 0.000 title claims abstract description 50
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 206010019668 Hepatic fibrosis Diseases 0.000 title claims abstract description 27
- 239000003937 drug carrier Substances 0.000 title abstract description 3
- 230000008685 targeting Effects 0.000 title description 3
- 230000009977 dual effect Effects 0.000 title 1
- 230000003278 mimic effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 43
- 229940079593 drug Drugs 0.000 claims abstract description 22
- 125000003118 aryl group Chemical group 0.000 claims abstract description 5
- 125000001424 substituent group Chemical group 0.000 claims abstract description 5
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 claims abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 51
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 238000003756 stirring Methods 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 18
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 238000004807 desolvation Methods 0.000 claims description 12
- 102000009027 Albumins Human genes 0.000 claims description 11
- 108010088751 Albumins Proteins 0.000 claims description 11
- -1 sec-amyl Chemical group 0.000 claims description 11
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 7
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 7
- 230000007935 neutral effect Effects 0.000 claims description 7
- 239000012266 salt solution Substances 0.000 claims description 7
- NCTHNHPAQAVBEB-WGCWOXMQSA-M sodium ferulate Chemical compound [Na+].COC1=CC(\C=C\C([O-])=O)=CC=C1O NCTHNHPAQAVBEB-WGCWOXMQSA-M 0.000 claims description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000004132 cross linking Methods 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 5
- HVIDUTFSQCOLKN-NSUKHAGXSA-N CC([C@@]([C@H]([C@H]1O)O)(O)O[C@H](CO)[C@H]1O)=O.[O] Chemical compound CC([C@@]([C@H]([C@H]1O)O)(O)O[C@H](CO)[C@H]1O)=O.[O] HVIDUTFSQCOLKN-NSUKHAGXSA-N 0.000 claims description 5
- HVIDUTFSQCOLKN-CEHJRZNHSA-N CC([C@]([C@H]([C@H]1O)O)(O)O[C@H](CO)[C@H]1O)=O.[O] Chemical compound CC([C@]([C@H]([C@H]1O)O)(O)O[C@H](CO)[C@H]1O)=O.[O] HVIDUTFSQCOLKN-CEHJRZNHSA-N 0.000 claims description 5
- 229940098773 bovine serum albumin Drugs 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 4
- 206010037660 Pyrexia Diseases 0.000 claims description 4
- 239000003431 cross linking reagent Substances 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 claims description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 3
- VBCVEPKUYJXQNV-UHFFFAOYSA-N Cinobufotoxin Natural products CC(=O)OC1C2OC22C3CCC4CC(OC(=O)CCCCCCC(=O)NC(CCCN=C(N)N)C(O)=O)CCC4(C)C3CCC2(C)C1C=1C=CC(=O)OC=1 VBCVEPKUYJXQNV-UHFFFAOYSA-N 0.000 claims description 3
- QEEBRPGZBVVINN-UHFFFAOYSA-N Desacetyl-bufotalin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C1(O)CCC2C=1C=CC(=O)OC=1 QEEBRPGZBVVINN-UHFFFAOYSA-N 0.000 claims description 3
- YPIQVCUJEKAZCP-UHFFFAOYSA-N Malotilate Chemical compound CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1 YPIQVCUJEKAZCP-UHFFFAOYSA-N 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- QEEBRPGZBVVINN-BMPKRDENSA-N bufalin Chemical compound C=1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5(CC[C@H](O)C[C@H]5CC4)C)CC[C@@]32C)C=CC(=O)OC=1 QEEBRPGZBVVINN-BMPKRDENSA-N 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- JYDJGHJTGIKKPD-JARWKFDMSA-N cino-bufotoxin Chemical compound C=1([C@@H]2[C@@]3(C)CCC4[C@@]5(C)CC[C@@H](C[C@H]5CCC4[C@@]43O[C@@H]4[C@@H]2OC(=O)C)OC(=O)CCCCCCC(=O)NC(CCCN=C(N)N)C(O)=O)C=COC(=O)C=1 JYDJGHJTGIKKPD-JARWKFDMSA-N 0.000 claims description 3
- 229960001338 colchicine Drugs 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 229950000470 malotilate Drugs 0.000 claims description 3
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 108090000942 Lactalbumin Proteins 0.000 claims description 2
- 102000004407 Lactalbumin Human genes 0.000 claims description 2
- 241001597008 Nomeidae Species 0.000 claims description 2
- 108010058846 Ovalbumin Proteins 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 108010071390 Serum Albumin Proteins 0.000 claims description 2
- 102000007562 Serum Albumin Human genes 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- VFRROHXSMXFLSN-KVTDHHQDSA-N aldehydo-D-mannose 6-phosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O VFRROHXSMXFLSN-KVTDHHQDSA-N 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- ORDAZKGHSNRHTD-UXHICEINSA-N deguelin Chemical compound O1C(C)(C)C=CC2=C1C=CC1=C2O[C@@H]2COC(C=C(C(=C3)OC)OC)=C3[C@@H]2C1=O ORDAZKGHSNRHTD-UXHICEINSA-N 0.000 claims description 2
- 230000013595 glycosylation Effects 0.000 claims description 2
- 238000006206 glycosylation reaction Methods 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 229940092253 ovalbumin Drugs 0.000 claims description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 238000010572 single replacement reaction Methods 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 abstract description 17
- 210000004027 cell Anatomy 0.000 abstract description 7
- 210000004024 hepatic stellate cell Anatomy 0.000 abstract description 5
- 210000004185 liver Anatomy 0.000 abstract description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract description 3
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 abstract description 3
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 abstract description 3
- 102000013275 Somatomedins Human genes 0.000 abstract description 3
- 206010057249 Phagocytosis Diseases 0.000 abstract description 2
- 239000003446 ligand Substances 0.000 abstract description 2
- 210000002540 macrophage Anatomy 0.000 abstract description 2
- 230000004048 modification Effects 0.000 abstract description 2
- 238000012986 modification Methods 0.000 abstract description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 abstract description 2
- 230000008782 phagocytosis Effects 0.000 abstract description 2
- 210000000952 spleen Anatomy 0.000 abstract description 2
- 210000003995 blood forming stem cell Anatomy 0.000 abstract 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical group NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 description 8
- 239000000843 powder Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 229960004756 ethanol Drugs 0.000 description 5
- 239000008176 lyophilized powder Substances 0.000 description 5
- 239000004531 microgranule Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- VXFVJCLMUVIKKX-LYFYHCNISA-N noviose Chemical compound CO[C@@H](C(C)(C)O)[C@@H](O)[C@@H](O)C=O VXFVJCLMUVIKKX-LYFYHCNISA-N 0.000 description 2
- BHTJEPVNHUUIPV-UHFFFAOYSA-N pentanedial;hydrate Chemical compound O.O=CCCCC=O BHTJEPVNHUUIPV-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- VQJHQYFOCBRCGA-QTVWNMPRSA-N (2s,3s,4s,5s)-6-amino-2,3,4,5,6-pentahydroxyhexanal Chemical compound NC(O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O VQJHQYFOCBRCGA-QTVWNMPRSA-N 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 102000003780 Clusterin Human genes 0.000 description 1
- 108090000197 Clusterin Proteins 0.000 description 1
- 235000004237 Crocus Nutrition 0.000 description 1
- 241000596148 Crocus Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000038460 IGF Type 2 Receptor Human genes 0.000 description 1
- 108010031792 IGF Type 2 Receptor Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000021463 dry cake Nutrition 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 239000010813 municipal solid waste Substances 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及医药技术领域，是一种双重靶向抗肝纤维化药物载体——拟糖蛋白纳米粒，即6-磷酸-甘露糖衍生物类白蛋白纳米粒及其制备方法。其化学结构通式如下：见右式，其中，R代表芳环上的取代基，M代表硫代碳酰二胺或偶氮基。本发明拟糖蛋白纳米粒可作为药物载体，首先通过肝、脾等处网状内皮系统的巨噬细胞的吞噬作用，将载有抗肝纤维化药物的纳米粒被动靶向于肝脏；还可通过结构修饰形成的特异性配体与肝星状细胞(hepatic stellate cell，HSC)中甘露糖-6-磷酸/胰岛素样生长因子(M6P/IGF II)受体特异结合，在细胞摄粒作用下进入细胞内部。拟糖蛋白纳米粒作为药物到达HSC的有效转运载体，使抗肝纤维化药物在HSC内部充分发挥作用，从而大大提高药物疗效。
The invention relates to the technical field of medicine, and relates to a dual-target anti-hepatic fibrosis drug carrier-mimicking glycoprotein nanoparticle, that is, a 6-phosphoric acid-mannose derivative albumin-like nanoparticle and a preparation method thereof. Its general chemical structure is as follows: see the formula on the right, wherein, R represents a substituent on the aromatic ring, and M represents thiocarbamide or azo group. The glycoprotein-mimicking nanoparticle of the present invention can be used as a drug carrier, firstly through the phagocytosis of macrophages in the reticuloendothelial system in the liver, spleen, etc., the nanoparticle loaded with anti-hepatic fibrosis drugs can be passively targeted to the liver; The specific ligand formed by structural modification specifically binds to the mannose-6-phosphate/insulin-like growth factor (M6P/IGF II) receptor in hepatic stellate cells (HSC), into the cell. Glycoprotein nanoparticles serve as an effective transporter for drugs to reach HSCs, so that anti-hepatic fibrosis drugs can fully play their role in HSCs, thereby greatly improving the efficacy of drugs.
Description
Technical field
The present invention relates to medical technical field, is a kind of pharmaceutical carrier of dual-target anti-hepatic fibrosis---Neoglycoproteins nanoparticle and preparation method thereof.
Background technology
Cell surface has special receptor, utilizes ligands specific to combine with microparticle surfaces, makes microgranule guiding cell, can change the bio distribution of microgranule.This class part has strong affinity to receptor, comprises the cell surface marker thing, as sugar, external source clusterin etc.Researcher is used sugar derivatives and is modified microgranule, can cause the targeting to leukocyte, alveolar sac, hepatocyte etc.Can discern galactose as hepatocyte, lung/core cell, fibrocyte can be discerned the Man-6-P ester, and leukocyte can be discerned 6-amino-mannose, and mononuclear phagocyte can be discerned mannose, N-acetyl-glucosamine.Find hepatic stellate cell (hepatic stellate cell after deliberation, HSC) under various impairment factors, can be activated and breed, make extracellular matrix synthetic in a large number, directly cause the formation of hepatic fibrosis, Man-6-P/insulin like growth factor among the HSC (M6P/IGF II) receptor, it is more to distribute in activation HSC.There is the 10%-20%M6P/IGF II receptor can be approximately directly at cell surface expression, its expression in the hepatic fibrosis process still can further increase, the Rd of cell surface is strengthened, Beljaars etc. with M6P to human albumin (Human Serum Albumin, HSA) modify, obtain Noviose protein carrier (M6P-HSA), can be by the HSC internalization, under endocytosis, enter cell interior (Beljaars L, Molema G, Weert B, et al.Albumin modified with mannose 6-phosphate:a potential carrier for selectivedelivery of antifibrotic drugs to rat and human hepatic stellate cell.Hepatology, 1999,29:1486-1493.).The complex that M6P-HSA and medicine form can be used as effective transport vehicle that medicine arrives HSC, and anti-hepatic fibrosis medicines is played a role in HSC inside.But only limit to the in vitro study of glycosyl modified albumin medicinal composition so far, not seeing has the appropriate formulation report.
Summary of the invention
The object of the invention provides a kind of dual-target anti-hepatic fibrosis medicines carrier---Neoglycoproteins nanoparticle and preparation method thereof.
Because the nanoparticulate carriers system has unique targeting; slow controlled release characteristics and protection drug effect; albuminous material is safety non-toxic again; non-immunogenicity; biodegradable; good biocompatibility; therefore after the present invention carries out the saccharifying structural modification with albumin; get Noviose protein nano grain by the desolvation legal system; it promptly is the nano_scale particle of substrate with the Neoglycoproteins; to enter in the body behind its medicine carrying; utilize the phagocytosis of the macrophage of the reticuloendothelial system that liver spleen etc. locates to enrich; the Neoglycoproteins nanoparticle passive target that is loaded with anti-hepatic fibrosis medicines is transported to liver etc. to be located; utilize Man-6-P/insulin like growth factor among Neoglycoproteins nanoparticle surface specific part and the HSC (M6P/IGF II) receptor-specific combination again; with the drug main moving-target to being transported to HSC; realize the active and passive dual-target of anti-hepatic fibrosis medicines; improve curative effect of medication greatly, reduce drug side effect.
Neoglycoproteins nanoparticle skeleton symbol of the present invention is
M6P represents 6-phosphomannose derivant, and general formula is as follows:
Wherein, the R group is represented the substituent group on the aromatic ring, substituting group position can be positioned at the neighbour,, para-position, can not have replacement, the single replacement, also can be polysubstituted, substituent group is selected from:
(1)H、F、Cl、Br、I；
(2) methyl, ethyl, propyl group, isopropyl, butyl, isobutyl group, the tert-butyl group, sec-butyl, amyl group, tertiary pentyl, sec-amyl, isopentyl, amido, cyano group, nitro, methoxyl group, ethyoxyl, propoxyl group, butoxy, isobutoxy, tert-butoxy, sec-butoxy;
The M group is represented the substituent group sulfo-carbonyl diamine that is connected with albumin nano granular surface amino groups acid residue on the aromatic ring
Or azo group: substituting group position can be positioned at the neighbour,, para-position, can singly replace, also can be polysubstituted;
The preferred 6-phosphoric acid-1-of M6P (4-sulfo-carbonyl diamine phenol)-α-D-mannopyranose, its R=H, M=4-sulfo-carbonyl diamine phenol;
N represents 1～60;
Albumin is selected from ovalbumin, lactalbumin, legumelin, serum albumin, and preferred bovine serum albumin (BovineSerum Albumin, BSA), the human albumin (Human Serum Albumin, HSA).
The preferred Neoglycoproteins nanoparticle of the present invention is 6-phosphoric acid-1-(4-sulfo-carbonyl diamine phenol)-α-D-mannopyranose albumin nano granular, preparation method is: by after paranitrophenol-α-D-mannopyranose phosphorylation again nitroreduction get para-aminophenol-6-phosphoric acid-α-D-mannopyranose (pap-M6P), activate back and albumin coupling with thiophosgene, get para-aminophenol-6-phosphoric acid-α-D-mannopyranose albumin, adopt the desolvation method more promptly.Reaction process is as follows:
Concrete steps are:
(1) five oxygen acetyl-β-the D-mannopyranose 1. in preparation
The D-mannose is at acetic anhydride: pyridine solution=8～12: 11～15, under-20 ℃～-5 ℃ conditions, react 4h, put again 0 ℃ 2 days, five oxygen acetyl-β-the D-mannopyranose 1.;
(2) acetyl-α-the D-mannopyranose 2. for preparation paranitrophenol-four oxygen
With paranitrophenol and five oxygen acetyl-β-D-mannopyranose 1. with ZnCl
2For catalyst in 160 ℃ the reaction 30min, paranitrophenol-four oxygen acetyl-α-the D-mannopyranose 2.;
(3) paranitrophenol-α-the D-mannopyranose 3. in preparation
2. paranitrophenol-four oxygen acetyl-α-D-mannopyranose in absolute methanol, adds NaOCH
3Reflux, paranitrophenol-α-the D-mannopyranose 3.;
(4) phosphoric acid-paranitrophenol-α-the D-mannopyranose 4. for preparation 6-
Paranitrophenol-α-D-mannopyranose is 3. at pyridine: acetonitrile: water=5～15: 20～30: in 0～2 solution with POCl
3React to such an extent that 6-phosphoric acid-paranitrophenol-α-the D-mannopyranose 4.;
(5) phosphoric acid-para-aminophenol-α-the D-mannopyranose 5. for preparation 6-
6-phosphoric acid-paranitrophenol-α-D-mannopyranose is 4. at methanol: water=3～9: in 1～3 the mixed liquor, under the Pa-C catalytic action, with H
2React to such an extent that 6-phosphoric acid-para-aminophenol-α-the D-mannopyranose 5.;
(6) (4-isothiocyanate phenol)-α-the D-mannopyranose 6. for preparation 6-phosphoric acid-1-
6-phosphoric acid-para-aminophenol-α-D-mannopyranose is 5. in ethanol and water=5～15: in 1～3 the mixed liquor, with CSCl
2React 6-phosphoric acid-1-(4-isothiocyanate phenol)-α-the D-mannopyranose 6.;
(7) preparation Neoglycoproteins [M6P] n-albumin 7.
6-phosphoric acid-1-(4-isothiocyanate phenol)-α-D-mannopyranose is aqueous solution 6., with bovine serum albumin or human albumin or other albuminous borate buffer solution room temperature reaction 18h, get Neoglycoproteins [M6P] n-albumin 7., 6. (1～800: 1) can get the different Neoglycoproteins of degree of glycosylation [M6P] n-albumin, n is 1～60 with albuminous ratio by adjusting 6-phosphoric acid-1-(4-isothiocyanate phenol)-α-D-mannopyranose;
(8) preparation Neoglycoproteins nanoparticle 8.
7. Neoglycoproteins is mixed with aqueous solution or is dissolved in 10mM NaCl or the KCl neutral salt solution, control pH value 5-11, stirring state continues to add an amount of desolvation agent down, the desolvation agent is selected from dehydrant ethanol, methanol, acetone etc., after forming the Neoglycoproteins nanoparticle, add an amount of cross-linking agent glutaraldehyde or methyl polyethylene-dextran or stabilizing agent lactic acid, continuous stirring is impelled the nanoparticle crosslinking curing more than 12 hours, get Neoglycoproteins nanoparticle colloidal suspension, ℃ spent the night in these suspension slight fever to 20～37, lyophilizing gets final product after removing resolvating agent, gained nanoparticle particle diameter 50-300nm.
The preparation method of carrying anti-hepatic fibrosis medicine Neoglycoproteins nanoparticle is:
In Neoglycoproteins [M6P] n-albumin aqueous solution or neutral salt solution 10mM NaCl or KCl 7., the water or the alcoholic solution that add the anti-hepatic fibrosis medicine, the anti-hepatic fibrosis medicine is selected from sodium ferulate, cinobufotoxin, bufalin, colchicine, Malotilate, control pH value 5-11, stirring state continues to add an amount of desolvation agent down, the desolvation agent is selected from dehydrant ethanol, methanol, acetone etc., after forming medicine carrying Neoglycoproteins nanoparticle, add an amount of cross-linking agent glutaraldehyde or methyl polyethylene-dextran or stabilizing agent lactic acid, continuous stirring is impelled the nanoparticle crosslinking curing more than 12 hours, gained medicine carrying Neoglycoproteins nanoparticle colloidal suspension is spent the night in 20～37 ℃ of following slight fevers, remove lyophilizing behind the resolvating agent, particle diameter be the nanoparticle of 50-300nm.If add proper amount of surfactant poloxamer or lecithin etc. simultaneously, can improve nanoparticle envelop rate and carrying drug ratio in the preparation process with anti-hepatic fibrosis medicines.
The specific embodiment
Now in conjunction with the embodiments, the present invention is described in detail
Embodiment oxygen acetyl-β-D-mannopyranose preparation 1. in 1: five
In the 500ml round-bottomed flask, add acetic anhydride 200ml, pyridine 260ml, cryosel is bathed and is cooled to-15 ℃, adds D-mannose 24g in half an hour in batches, stirs 4h, the gained colorless cleared solution put 0 ℃ 2 days, jolting therebetween is several times.Slowly pour into after solution firmly shakes up in the 3L water that contains trash ice, stir 45min, crystallization is separated out, and filters, and filter cake washes after drying with water and spends the night, and gets 1. 40.3g of white powder five oxygen acetyl-β-D-mannopyranose, productive rate 77.5%.ESI-MS(positive-ion?mode)：413.02(M+Na
+，100％)。1H?NMR(D
2O)：1.94-2.17(m，15H，CH
3CO)，4.07-5.97(m，7H，C
1-6-H)。
Embodiment 2: paranitrophenol-four oxygen acetyl-α-D-mannopyranose preparation 2.
Add paranitrophenol 15g in the 500ml round-bottomed flask, five oxygen acetyl-β-D-mannopyranose is 15g 1., ZnCl
20.6g oil bath is heated to 160 ℃, stirs 30min, the black fused mass is cooled to 70 ℃, slowly adds benzole soln 240ml, and after the gained brown solution washed with water, it was almost colourless then to be washed till water layer with 1mol/l NaOH, washes anhydrous CaCl again with water
2Drying to crocus syrupy shape liquid, adds an amount of anhydrous alcohol solution in 35 ℃ of evaporated under reduced pressure, (35 ℃ of activated carbon decolorizings, 20min), be evaporated to crystal once more and separated out, the room temperature cooling is placed on-20 ℃ and spends the night, separate out a large amount of crystal filter white powder, be paranitrophenol-four oxygen acetyl-α-D-mannopyranose 2., mother solution can further concentrate recrystallization and get product 2., amounts to 11.3g, productive rate 62.8%, ([α]
20D+93 ° of cl, chloroform).Also activated carbon decolorizing gained solution can be used column chromatography separating purification (ethyl acetate-petroleum ether, 1: 2) after 30 ℃ of evaporated under reduced pressure, eluent gets white powder in 30 ℃ of drying under reduced pressure.(the thin layer chromatography developing solvent: ethyl acetate-petroleum ether, 1: 2, Rf=0.38).ESI-MS(positive-ionmode)：492.15(M+Na
+，100％)。1H?NMR(CDCl
3)：8.23(d，2H，J＝9.1Hz，Ar-H-meta)，7.21(d，2H，J＝9.1Hz，Ar-H-ortho)，2.11(m，12H，CH
3CO)，4.00-5.63(m，7H，C
1-6-H)。
Embodiment 3: paranitrophenol-α-D-mannopyranose preparation 3.
Add absolute methanol 96ml in the 250ml three-necked bottle, paranitrophenol-four oxygen acetyl-α-D-mannopyranose is 8g 2., stir suspension, add 0.2mol/l NaOCH
31.2ml, be heated to backflow 8min, to separate out in 30 ℃ of evaporated under reduced pressure to crystal, room temperature cooling is placed on-20 ℃, spends the night, and filters after drying and gets white powder, be i.e. 3. 3.5g of paranitrophenol-α-D-mannopyranose, productive rate 68.7%.([α]
20D+145 ° of c 0.2, water), (thin layer chromatography developing solvent: CHCl
3/ MeOH/H
2O, 13: 8: 2, Rf=0.86).ESI-MS(negtive-ion?mode)：346.05(M+HCOOH-1，100％)。1H?NMR(D
2O)：8.25(d，2H，J＝9Hz，Ar-H-meta)，7.28(d，2H，J＝9Hz，Ar-H-ortho)，5.77(s，1H，C
1-H)，3.61-4.19(m，6H，C
2-5，
6a，6b-H)。
Embodiment 4:6-phosphoric acid-paranitrophenol-α-D-mannopyranose preparation 4.
In the 25ml round-bottomed flask, add pyridine 2.8ml, acetonitrile 7ml, water 0.28ml, the back that stirs adds 3. 2.1g of paranitrophenol-α-D-mannopyranose, slowly is added dropwise to POCl under the condition of ice bath
32.8ml, stirring 1.5h, the gained settled solution is poured into and 84g is housed on ice, and after the thawing, regulating pH with 2.5mol/l NaOH is 7.0, uses column chromatography separating purification (MeOH-DCM, 1: 1) (developing solvent: CHCl after 30 ℃ of evaporated under reduced pressure
3/ MeOH/H
2O, 13: 8: 2, Rf=0.29), eluent got white powder in 30 ℃ of drying under reduced pressure, i.e. 4. 1.85g of 6-phosphoric acid-paranitrophenol-α-D-mannopyranose, productive rate 69.5%.ESI-MS(negtive-ion?mode)：380.00(M-1，100％)。1H?NMR(D
2O)：8.12(d，2H，J＝8.7Hz，Ar-H-meta)，7.15(d，2H，J＝8.9Hz，Ar-H-ortho)，5.63(s，1H，C
1-H)，3.60-4.07(m，6H，C
2-5，
6a，6b-H)。
Embodiment 5:6-phosphoric acid-para-aminophenol-α-D-mannopyranose preparation 5.
The mixed liquor (6: 1 that in the 100ml three-necked bottle, adds 49ml methanol and water, v/v), 6-phosphoric acid-paranitrophenol-α-D-mannopyranose is 0.7g 4., 10%Pa-C 0.075g, gained suspension room temperature, normal pressure, the down logical H2 stream of stirring 4h, thin layer chromatography (TLC) monitoring reaction.In 30 ℃ of evaporated under reduced pressure to 3-4ml, the adularescent crystal is separated out, sucking filtration is removed, and filtrate is concentrated into 2ml, adds an amount of methanol, a large amount of yellowish-brown solids are separated out, sucking filtration, filter cake is washed with methanol, and filtrate is continued evaporated under reduced pressure and is got brown solid, merging with dry cake before is 5. 0.55g of product 6-phosphoric acid-para-aminophenol-α-D-mannopyranose, productive rate 85.9%.(thin layer chromatography developing solvent: CHCl
3/ MeOH/H
2O, 13: 8: 2, Rf=0.14).ESI-MS(negtive-ion?mode)：350.00(M-1，100％)。1H?NMR(D
2O)：7.07(d，2H，J＝8.9Hz，Ar-H-meta)，7.02(d，2H，J＝8.9Hz，Ar-H-ortho)，5.48(s，1H，C
1-H)，4.12-3.49(m，6H，C
2-5，
6a，6b-H)。
Embodiment 6:6-phosphoric acid-1-(4-isothiocyanate phenol)-α-D-mannopyranose preparation 6.
(9: 1, v/v), 6-phosphoric acid-para-aminophenol-α-D-mannopyranose is 0.217g (0.62mmol) 5., slowly is added dropwise to CSCl under the condition of ice bath for the mixed liquor of adding 50ml dehydrated alcohol and water in the 100ml round-bottomed flask
20.27ml (3.5mmol), stir 2h, uncovered logical N
2Stir 3h, transferring pH with 0.1mol/lNaOH under the condition of ice bath is 6.0, gets yellow solid in 30 ℃ of evaporated under reduced pressure, with column chromatography separating purification (CHCl
3/ MeOH/H
2O, 13: 8: 2) (developing solvent: CHCl
3/ MeOH/H
2O, 13: 8: 2, Rf=0.43), eluent got buff powder in 30 ℃ of evaporated under reduced pressure, i.e. 6. 0.225g of product 6-phosphoric acid-1-(4-isothiocyanate phenol)-α-D-mannopyranose, productive rate 92.2% is in-20 ℃ of preservations.ESI-MS(negative-ion?mode)：392.03(M-1，100％)。1H?NMR(D
2O)：7.26(d，2H，Ar-H-meta)，7.10(d，2H，Ar-H-ortho)，5.54(s，1H，C
1-H)，3.45-4.09(m，6H，C
2-5，
6a，6b-H)。
Embodiment 7: the preparation of Neoglycoproteins [M6P] n-BSA lyophilized powder
Get 6. 35.37mg (0.09mmol) of 6-phosphoric acid-1-(4-isothiocyanate phenol)-α-D-mannopyranose, be dissolved in the 5ml distilled water, get sugar derivatives solution.In the 20ml round-bottomed flask, add BSA21.78mg (0.23 μ mol), borate buffer solution 7.5ml (pH 9.0), slowly add sugar derivatives solution again, stirring at room 18h, gained solution 0.15mol/lNaCl (1000ml), distilled water (2000ml) dialysis, the dialysis solution lyophilizing gets white powder, i.e. target product Neoglycoproteins [M6P]
3-BSA.Crude product is through sephadex G-25 column separating purification, and 0.15mol/l NaCl is an eluent, and lyophilizing promptly.
Embodiment 8: the preparation 8. of Neoglycoproteins nanoparticle
Precision takes by weighing 30mg Neoglycoproteins lyophilized powder, is dissolved in the 4.0ml distilled water, and pH value is 8.5, and the speed with 0.5ml/min under the stirring at room continues to add 7.0ml 95% ethanol, can form the Neoglycoproteins nanoparticle.Behind the desolvation, add 8% glutaraldehyde water solution, 30 μ l and make microgranule crosslinked, stir more than the 12h simultaneously in the cross-linking process.Gained Neoglycoproteins nanoparticle 8., particle diameter is 50-300nm.
The Neoglycoproteins lyophilized powder is dissolved among the neutral salt solution 10mMNaCl (or KCl), and method is the same, also can make the Neoglycoproteins nanoparticle, and particle diameter is 50-300nm.
Embodiment 9: the preparation of carrying anti-hepatic fibrosis medicine sodium ferulate Neoglycoproteins nanoparticle
7. precision takes by weighing 30mg Neoglycoproteins lyophilized powder, be dissolved in the 4.0ml distilled water, anti-hepatic fibrosis medicine sodium ferulate aqueous solution (or alcoholic solution) 2.0ml that adds 5mg/ml again, pH value is 8, speed with 0.5ml/min under the stirring at room continues to add 5.0ml 95% ethanol, can form sodium ferulate Neoglycoproteins nanoparticle.Behind the desolvation, add 8% glutaraldehyde water solution, 10 μ l and make microgranule crosslinked, stir more than the 12h simultaneously in the cross-linking process.Gained sodium ferulate Neoglycoproteins nanoparticle particle diameter is 50-300nm.
The Neoglycoproteins lyophilized powder is dissolved among the neutral salt solution 10mMNaCl (or KCl), and method also can make sodium ferulate Neoglycoproteins nanoparticle with embodiment 9, and particle diameter is 50-300nm.
The preparation method of other anti-hepatic fibrosis medicines such as cinobufotoxin, bufalin, colchicine, Malotilate Neoglycoproteins nanoparticle is with embodiment 9.
Neoglycoproteins 10～300mg and anti-hepatic fibrosis medicine 1～200mg are with＞1 arbitrary proportion in 4.0ml distilled water or neutral salt solution, adopt the method identical to be prepared with embodiment 9, can obtain anti-hepatic fibrosis medicine Neoglycoproteins nanoparticle equally, particle diameter is 50～300nm.
Common anti-hepatic fibrosis medicines preparation enters whole body distribution in the body, and dosage is just big, not only wastes medicine, and can cause toxicity.And the present invention has realized the dual-target administration, and medicine is concentrated in HSC, can reduce dosage, has not only given full play to the therapeutical effect of medicine, and has reduced poisonous side effect of medicine, and is significant to effective control of hepatic fibrosis.
Claims (6)
1. medicine carrier pseudoglucoprotein nano particle of double-target anti-liver-fibrosis
Wherein M6P represents 6-phosphomannose derivant, and general structure is as follows:
The R group is represented the substituent group on the aromatic ring, substituting group position can be positioned at the neighbour,, para-position, can not have replacement, the single replacement, also can be polysubstituted, substituent group is selected from:
(1)H、F、Cl、Br、I；
(2) methyl, ethyl, propyl group, isopropyl, butyl, isobutyl group, the tert-butyl group, sec-butyl, amyl group, tertiary pentyl, sec-amyl, isopentyl, amido, cyano group, nitro, methoxyl group, ethyoxyl, propoxyl group, butoxy, isobutoxy, tert-butoxy, sec-butoxy;
The M group is represented substituent group sulfo-carbonyl diamine or the azo group that is connected with albumin nano granular surface amino groups acid residue on the aromatic ring; Substituting group position can be positioned at the neighbour,, para-position, can singly replace, also can be polysubstituted;
N represents 1～60;
Albumin is selected from serum albumin, ovalbumin, lactalbumin, legumelin.
2. by the described Neoglycoproteins nanoparticle of claim 1, it is characterized in that R is H, M is a 4-sulfo-carbonyl diamine phenol, and albumin is human albumin or bovine serum albumin, and it is 6-phosphoric acid-1-(4-sulfo-carbonyl diamine phenol)-α-D-mannopyranose protein nano grain;
3. the preparation method of the described 6-phosphoric acid-1-of claim 2 (4-sulfo-carbonyl diamine phenol)-α-D-mannopyranose protein nano grain, synthetic route is as follows:
Concrete steps are:
(1) five oxygen acetyl-β-the D-mannopyranose 1. in preparation
The D-mannose is at acetic anhydride: pyridine solution=8～12: 11～15, under-20 ℃～-5 ℃ conditions, react 4h, put again 0 ℃ 2 days, five oxygen acetyl-β-the D-mannopyranose 1.;
(2) acetyl-α-the D-mannopyranose 2. for preparation paranitrophenol-four oxygen
With paranitrophenol and five oxygen acetyl-β-D-mannopyranose 1. with ZnCl
2For catalyst in 160 ℃ the reaction 30min, paranitrophenol-four oxygen acetyl-α-the D-mannopyranose 2.;
(3) paranitrophenol-α-the D-mannopyranose 3. in preparation
2. paranitrophenol-four oxygen acetyl-α-D-mannopyranose in absolute methanol, adds NaOCH
3Reflux, paranitrophenol-α-the D-mannopyranose 3.;
(4) phosphoric acid-paranitrophenol-α-the D-mannopyranose 4. for preparation 6-
Paranitrophenol-α-D-mannopyranose is 3. at pyridine: acetonitrile: water=5～15: 20～30: in 0～2 solution with POCl
3React to such an extent that 6-phosphoric acid-paranitrophenol-α-the D-mannopyranose 4.;
(5) phosphoric acid-para-aminophenol-α-the D-mannopyranose 5. for preparation 6-
6-phosphoric acid-paranitrophenol-α-D-mannopyranose is 4. at methanol: water=3～9: in 1～3 the mixed liquor, under the Pa-C catalytic action, with H
2React to such an extent that 6-phosphoric acid-para-aminophenol-α-the D-mannopyranose 5.;
(6) (4-isothiocyanate phenol)-α-the D-mannopyranose 6. for preparation 6-phosphoric acid-1-
6-phosphoric acid-para-aminophenol-α-D-mannopyranose is 5. in ethanol and water=5～15: in 1～3 the mixed liquor, with CSCl
2React 6-phosphoric acid-1-(4-isothiocyanate phenol)-α-the D-mannopyranose 6.;
(7) preparation Neoglycoproteins [M6P] n-albumin 7.
6-phosphoric acid-1-(4-isothiocyanate phenol)-α-D-mannopyranose is aqueous solution 6., with bovine serum albumin or human albumin or other albuminous borate buffer solution room temperature reaction 18h, get Neoglycoproteins [M6P] n-albumin 7., by adjust 6-phosphoric acid-1-(4-isothiocyanate phenol)-α-D-mannopyranose 6. with albuminous ratio 1～800: 1, can get the different Neoglycoproteins of degree of glycosylation [M6P] n-albumin, n is 1～60;
(8) preparation Neoglycoproteins nanoparticle 8.
7. Neoglycoproteins is mixed with aqueous solution or is dissolved in 10mM NaCl or the KCl neutral salt solution, control pH value 5-11, stirring state continues to add an amount of desolvation agent down, the desolvation agent is selected from dehydrant ethanol, methanol, acetone, after forming the Neoglycoproteins nanoparticle, add an amount of cross-linking agent glutaraldehyde or methyl polyethylene-dextran or stabilizing agent lactic acid, continuous stirring is impelled the nanoparticle crosslinking curing more than 12 hours, get Neoglycoproteins nanoparticle colloidal suspension, ℃ spent the night in these suspension slight fever to 20～37, lyophilizing gets final product after removing resolvating agent, gained nanoparticle particle diameter 50-300nm.
4. the application in the preparation anti-hepatic fibrosis medicines by claim 1 or 2 or 3 described Neoglycoproteins nanoparticles.
5. carry anti-hepatic fibrosis medicines Neoglycoproteins nanoparticle preparation method, it is characterized in that 7. the described Neoglycoproteins of claim 3 [M6P] n-albumin is made into finite concentration aqueous solution or neutral salt solution, the aqueous solution or the alcoholic solution that add anti-hepatic fibrosis medicines, anti-hepatic fibrosis medicines is selected from sodium ferulate, cinobufotoxin, bufalin, colchicine, Malotilate, control pH value 5-11, stirring state continues to add an amount of desolvation agent down, the desolvation agent is selected from dehydrant ethanol, methanol, acetone, after forming medicine carrying Neoglycoproteins nanoparticle, add an amount of cross-linking agent glutaraldehyde or methyl polyethylene-dextran or stabilizing agent lactic acid, continuous stirring is impelled the nanoparticle crosslinking curing more than 12 hours, gained medicine carrying Neoglycoproteins nanoparticle colloidal suspension is spent the night in 20～37 ℃ of following slight fevers, remove resolvating agent after lyophilizing get final product.
6. by the described medicine carrying Neoglycoproteins of claim 5 nanoparticle preparation method, it is characterized in that when adding anti-hepatic fibrosis medicines, also adding proper amount of surfactant poloxamer or lecithin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100297841A CN100368022C (en) | 2005-09-20 | 2005-09-20 | Dual targeting anti-hepatic fibrosis drug carrier mimic glycoprotein nanoparticle and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100297841A CN100368022C (en) | 2005-09-20 | 2005-09-20 | Dual targeting anti-hepatic fibrosis drug carrier mimic glycoprotein nanoparticle and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1743009A CN1743009A (en) | 2006-03-08 |
| CN100368022C true CN100368022C (en) | 2008-02-13 |
Family
ID=36138632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100297841A Expired - Fee Related CN100368022C (en) | 2005-09-20 | 2005-09-20 | Dual targeting anti-hepatic fibrosis drug carrier mimic glycoprotein nanoparticle and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100368022C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018141678A1 (en) * | 2017-01-31 | 2018-08-09 | Medizinische Hochschule Hannover (Mhh) | Natural compounds and fibrosis |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102940621B (en) * | 2012-11-27 | 2014-08-13 | 桂林医学院 | Application of methyl ferulic acid in preparation of medicine for preventing and curing hepatic fibrosis |
| CN104725442B (en) * | 2015-04-15 | 2018-02-02 | 湘潭大学 | A kind of method for preparing p-nitrophenyl α D mannopyranose glycosides |
| CN106432371A (en) * | 2016-10-31 | 2017-02-22 | 中国人民解放军第二军医大学 | Beta-1,2-D-oligomeric mannoprotein conjugates and preparation method and application thereof |
| CA3067247A1 (en) | 2017-07-11 | 2019-01-17 | Alexion Pharmaceuticals, Inc. | Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof |
-
2005
- 2005-09-20 CN CNB2005100297841A patent/CN100368022C/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| Albumin modified with mannose 6-phosphate:a potentialcarrier for selective delivery of antifibrotic drugs to rat andhuman hepatic stellate cell. Beljaars L, Molema G, Weert B等.Hepatology,Vol.29 . 1999 * |
| Characeristics of the hepatic stellate cell-selective carriermannose 6-phosphate modified albumin(M6P28-HSA). Beljaars L, Olinga P, Molema G等.liver,Vol.21 . 2001 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018141678A1 (en) * | 2017-01-31 | 2018-08-09 | Medizinische Hochschule Hannover (Mhh) | Natural compounds and fibrosis |
| US11185539B2 (en) | 2017-01-31 | 2021-11-30 | Medizinische Hochschule Hannover (Mhh) | Natural compounds and fibrosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1743009A (en) | 2006-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Microencapsulation using natural polysaccharides for drug delivery and cell implantation | |
| Fedosov | Physiological and molecular aspects of cobalamin transport | |
| KR0134982B1 (en) | Lipsome microreservoir composition and method | |
| CN107158014B (en) | Carrier-free assembles cancer target anticancer nano drug and the preparation method and application thereof altogether | |
| US11850309B2 (en) | Cationic materials and formulations for drug delivery | |
| US20030224037A1 (en) | Liposome preparation | |
| PT725648E (en) | PHARMACOLOGICALLY ACTIVE HEPATOSELECTIVE AGENTS. | |
| KR101512702B1 (en) | Liver targeted drug delivery systems using metal nanoparticles and preparing method thereof | |
| CN105708848A (en) | Environmentally responsive tumor targeted combined administration transfer system | |
| KR20080100376A (en) | Active Agent-Concentrated Nanoparticles Based on Hydrophilic Proteins | |
| CA2150617C (en) | Nanoerythrosome as bioactive agent carrier | |
| Li et al. | The glucose-lowering potential of exenatide delivered orally via goblet cell-targeting nanoparticles | |
| CN100368022C (en) | Dual targeting anti-hepatic fibrosis drug carrier mimic glycoprotein nanoparticle and its preparation method | |
| US20210228725A1 (en) | Drug delivery | |
| US20060029586A1 (en) | Use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates | |
| CN101095670A (en) | Luteolin phospholipid complexes and method for preparing the same and application thereof | |
| Porterfield et al. | Galactosylated hydroxyl‐polyamidoamine dendrimer targets hepatocytes and improves therapeutic outcomes in a severe model of acetaminophen poisoning‐induced liver failure | |
| AU666541B2 (en) | Pharmaceutical composition having site-specific delivery | |
| WO2008052722A2 (en) | Use of ribavirin-conjugates as an anti-viral drug | |
| CN108478532B (en) | Preparation method of β-cyclodextrin-dipalmito liposome and its application as drug carrier | |
| CN111110861A (en) | Human serum albumin-based drug-loaded particles and preparation method thereof | |
| MX2010014087A (en) | Drug carrier. | |
| AU2019388940B2 (en) | Drug containing liver targeting specific ligand and thyroid hormone receptor agonist | |
| CN109761915B (en) | 5-fluorouracil ester-forming prodrugs targeting the MCT1 transporter | |
| JP2005508970A (en) | Anti-diabetic 2-substituted-5'-O- (1-boranotriphosphate) adenosine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080213 Termination date: 20110920 |